Modus Therapeutics has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease.

The patent application is based on novel preclinical work that was undertaken in an established kidney disease animal model during an academic collaboration project. A granted patent would provide patent protection until at least 2043.

Sevuparin is a compound of Modus Therapeutics, currently being evaluated in Phase 1 clinical trials as a potential treatment for sepsis and septic shock, as well as for severe malaria in children.

“Sevuparin is already in development as a potential new treatment for sepsis and septic shock. In addition, we are actively evaluating new avenues for development and commercialization of our key asset, as well as continuously developing its patent portfolio in parallel. While the patent application is a tangible result of these efforts, it also demonstrates Modus´ ability to successfully collaborate internationally with leading academic institutions,” says John Öhd, CEO of Modus Therapeutics.

Photo of John Öhd